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Abstract
Coxiella burnetii is an obligate intracellular Gram-negative bacterium that causes acute Q fever and chronic infections in
humans. A killed, whole cell vaccine is efficacious, but vaccination can result in severe local or systemic adverse reactions.
Although T cell responses are considered pivotal for vaccine derived protective immunity, the epitope targets of CD4+ T cell
responses in C. burnetii vaccination have not been elucidated. Since mapping CD4+ epitopes in a genome with over 2,000
ORFs is resource intensive, we focused on 7 antigens that were known to be targeted by antibody responses. 117 candidate
peptides were selected from these antigens based on bioinformatics predictions of binding to the murine MHC class II
molecule H-2 IAb. We screened these peptides for recognition by IFN-c producing CD4+ T cell in phase I C. burnetii whole cell
vaccine (PI-WCV) vaccinated C57BL/6 mice and identified 8 distinct epitopes from four different proteins. The identified
epitope targets account for 8% of the total vaccination induced IFN-c producing CD4+ T cells. Given that less than 0.4% of
the antigens contained in C. burnetii were screened, this suggests that prioritizing antigens targeted by antibody responses
is an efficient strategy to identify at least a subset of CD4+ targets in large pathogens. Finally, we examined the nature of
linkage between CD4+ T cell and antibody responses in PI-WCV vaccinated mice. We found a surprisingly non-uniform
pattern in the help provided by epitope specific CD4+ T cells for antibody production, which can be specific for the epitope
source antigen as well as non-specific. This suggests that a complete map of CD4+ response targets in PI-WCV vaccinated
mice will likely include antigens against which no antibody responses are made.
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Introduction
Coxiella burnetii is an obligate intracellular bacterium that causes
Q fever in humans and animals. It is highly infectious and causes a
wide variety of disease manifestations in humans as asymptomatic,
acute and chronic forms [1,2]. An effective formalin killed whole
cell vaccine (Q-VaxH), produced from the phase I Henzerling
strain of C. burnetii, has been administered to individuals that are
skin test and serologically negative in Australia [3,4], but no
licensed vaccine exists in the US. Unfortunately, vaccination can
result in severe local or systemic adverse reactions when
administered to previously infected populations, and repeat
vaccination can induce severe persistent reactions [4,5]. To
develop safe and effective new vaccines, it is therefore important
to understand protective immune responses against C. burnetii that
are induced by existing vaccines.
Several lines of evidence suggest that T cell dependent immune
responses, especially CD4+ T cells, are induced by C. burnetii
vaccines, and play a critical role in protective immunity against
infection. Adoptive transfer of T cells from mice immunized with
inactivated phase I C. burnetii whole cell vaccine (PI-WCV) was
shown to provide protection for recipient mice [6], confirming the
results from early studies [7,8]. The fact that a major part of the
vaccine-derived humoral response consists of IgG antibodies
directed against proteins [9,10] indicates the presence of relevant
helper CD4+ T cell responses. Finally, low dose C. burnetii infection
causes death in SCID and T cell deficient mice, but does not show
a phenotype in B cell deficient mice, suggesting that T cells are
essential for host resistance to C. burnetii infection [11].
Antigen specific CD4+ T cells generate protective immunity
through different mechanisms: 1) the provision of cognate help to
B cells, a requisite event for immunoglobulin (Ig) switching and
affinity maturation in B cells [12,13], 2) control of CD8+ T cells
expansion and death, which appears to be essential for long-term
CD8 memory responses [14,15], and 3) direct secretion of
cytokines including IFN-c and TNF-a. The latter has been shown
to be critical for intracellular bacterial clearance in general, and
for C. burnetii in particular [11,16,17,18,19]. IFN-c stimulates the
production of nitric oxide and reactive oxygen molecules in
macrophages, which are responsible for controlling infection
[20,21]. Treatment with IFN-c may also induce C. burnetii killing
by restoring the ability of the phagosome to mature and by
promoting apoptosis of infected monocytes [22]. Consequently,
IFN-c has been successfully tested to treat chronic Q fever in a
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patient not responding to antibiotic treatment [23]. Inducing
CD4+ T cells as a major source of IFN-c is therefore highly
desirable for vaccine-derived protective immunity.
The specific molecular targets of CD4+ T cell responses induced by
C. burnetii PI-WCV vaccination are not known. Their identification
could help guide which antigens to include in a new subunit vaccine,
help develop correlates of protection for cellular immunity, and allow
the use of tetramer reagents to elucidate the phenotypes and role of
vaccine induced CD4+ T cells. Unfortunately, identifying targets of
CD4+ responses is not trivial for bacterial pathogens for at least two
reasons. The number of proteins encoded in the C. burnetii genome is
large and most of them are thought to be included in the whole cell
vaccine. This means a large number of potential targets needs to be
included in the screen. Equally important, the frequency of
responding CD4+ cells for a particular target protein is typically
low. This means a strong stimulus and/or a highly sensitive assay is
needed to reliably detect a response.
Previous studies that successfully identified targets of CD4+
responses in complex pathogens such as Mycobacterium and
Salmonella [24,25,26] have focused on antigens targeted by B cell
response. However, the success of this approach seemed to be at
odds with classical studies of CD4+ responses that showed no linkage
between antigens recognized by CD4+ and B cell responses, but
rather a predominance of ‘intermolecular help’ [27,28,29,30]. This
apparent contradiction may be explained by a recent study that
found a strong correlation between CD4+ and antibody responses
on the antigen level in vaccinia virus infected mice [31]. The
authors of that study suggested that classical investigations of linkage
between CD4+ and B cell response targets might not have
encountered this effect because they were examining small viral
pathogens such as influenza or hepatitis B virus.
In this study, we utilized bioinformatic predictions to identify
candidate peptide epitopes in a set of C. burnetii antigens that were
previously shown to be targets of immunodominant B cell
responses. We identified eight H-2 I-Ab restricted C. burnetii
CD4+ T cell epitopes in four antigens which elicited high IFN-c
production following vaccination. This is the first set of T cell
epitopes identified in C. burnetii and this strategy can guide future
studies in subunit vaccine development against Q fever.
Results
Selection of a candidate set of targets for CD4+ responses
following PI-WCV vaccination
The humoral responses following C. burnetii infection and
vaccination has been shown to be directed against both protein
and glycolipid fractions of C. burnetii [32,33,34,35]. The fact that a
major part of the response consists of IgG antibodies directed
against proteins [33,35] indicates the presence of relevant CD4+ T
helper cell response. Protein microarrays using a group of
vaccinated and convalescent human sera have identified a set of
C. burnetii immunodominant proteins [36]. Of these four
immunodominant proteins (CBU 0008, CBU 0383, CUB1157,
CBU 1869), two previously identified immunodominant proteins
(CBU 0311 [37] CBU 1910 [32]) and one previously unpublished
antigen (CBU 1645, personal observation) were selected (Table 1)
and tested for recognition by antibodies in PI-WCV vaccinated
C57BL/6 wild type mice (Figure 1). Prime and boost PI-WCV
vaccination generated detectable IgG responses against all seven
recombinant antigens in C57BL/6 wild type mice. Antibody
responses were also measured in vaccinated C57BL/6 MHCII
deficient (H2-Ab2/2) mice, in which no significant IgG production
was detected against any of the individual antigens. This confirms
that IgG production against all tested proteins is MHCII
dependent and provides further evidence for the presence of
vaccine induced CD4+ T cells.
We next wanted to examine if the immunodominant B cell
antigens in C. burnetii are also targets of CD4+ responses. We
screened the sequences of the seven B cell antigens (Table 1) for
peptides predicted to have high affinity for the MHC class II
molecule H-2 IAb using a consensus prediction approach (see
Materials and Methods and [38]). A set of 117 candidate peptide
sequences, 15 residues in length, were selected from the 7 different
antigens, and synthesized for further study.
Identification of H2 I-Ab restricted epitopes in vaccinated
C57BL/6 mice
In an initial screen, the antigenicity of the 117 candidate
peptides was tested using cells from C57BL/6 mice obtained 10
days following s.c. vaccination with each recombinant protein in
the context of complete Freud’s adjuvant (CFA). Responses were
evaluated in IFN-c ELISPOT assay with CD4+ T cells purified
from individually pooled spleen and lymph nodes of 5 mice. The
number of spot forming cells (SFC) following peptide stimulation
was recorded in triplicate along with media stimulated cells as
negative controls. Any peptide yielding .20 mean net SFC/106
cells above background and a Stimulation Index (SI = SFC
peptide/SFC media control) .2 with a p,0.05 in a standard t
test in two independent experiments was considered positive. A
total of 20 positive peptides with SI values between a range of 2
and 19 were identified (Table S1). In contrast, none of the peptides
elicited positive responses in naı¨ve mice (data not shown).
Table 1. Summary of antigen and peptide selection.
ORF ID Protein Functiona Putative localizationb Protein length (aa)
Number of predicted I-Ab
binding peptides
CBU 0008 Hypothetical protein Unknown 62 12
CBU 0311 Outer membrane porin Outer membrane 223 29
CBU 0383 DNA-3-methyladenine glycosylase Cytoplasmic 204 8
CBU 1157 Hypothetical exported lipoprotein Cytoplasmic Membrane 233 12
CBU 1645 Type IV secretion DotB protein Cytoplasmic 372 25
CBU 1869 Hypothetical exported protein Unknown 217 8
CBU 1910 Outer membrane protein Periplasmic/Outer membrane 252 23
aTIGR annotations.
bPredicted by PSORTb [56].
doi:10.1371/journal.pone.0017712.t001
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Peptides that were positive in the initial screens were tested for
recognition by CD4+ T cells purified from 6 C57BL/6 mice 10
days post s.c. vaccination of PI-WCV homogenized with
incomplete Freud’s adjuvant (IFA) and CpG. A total of 11 out
of 20 originally identified peptides elicited positive responses
following PI-WCV vaccination (.20 SFC/106 cells, SI.2 with a
p,0.05). This included three pairs of peptides that overlapped by
11 or more residues and therefore are likely recognized by the
same T cells. For each of these pairs, the peptide with the higher
response following WCV vaccination was chosen as the optimal
representative, resulting in a total of 8 distinct epitopes from 4
different C. burnetii proteins (Table 2). The eight identified CD4+
epitopes are conserved among all sequenced C. burnetii strains, and
we did not find any identical sequences in other bacteria species by
BLAST.
Infection and vaccination induced similar epitope
recognition hierarchy
We next wanted to determine if the epitopes identified in
vaccinated mice overlap with those recognized in infected mice.
All peptides listed in Table S1 were tested for recognition by
purified CD4+ T cells derived from C. burnetii RSA 439 infected
C57BL/6 mice. A total of 9 out of 20 originally identified peptides
elicited positive responses following 106 RSA 439 intratracheal
Figure 1. IgG antibody production for selected C. burnetii proteins is MHC-II dependent. Seven recombinant proteins were generated and
tested by ELISA for IgG reactivity of PI-WCV vaccinated C57BL/6 mice, C57BL/6 MHCII deficient (H2-Ab2/2) mice and PBS vaccinated C57BL/6 mice
sera, 14-day post second vaccination. C. burnetii lysate was included as a positive control. PI-WCV vaccinated B6 mice generated detectable IgG
responses against all antigens tested, while MHCII deficient mice showed no detectable IgG responses against individual recombinant proteins and
only weak responses against C. burnetii lysate. *P,0.05, **P,0.01, ***P,0.001 comparing to PBS vaccinated B6 mice.
doi:10.1371/journal.pone.0017712.g001
Table 2. Summary of distinct CD4+ T cell epitopes recognized after vaccination with recombinant proteins and PI-WCV.
Peptide ID Sequence
H-2 I-Ab binding
affinity [IC50 nM] IFN-c T cell ELISPOT [SI]
after vaccinationa after infectionb
CBU 038369–83 RDSFNNFDASIISKY 507 5.3 4.4
CBU 115763–77 PWRYIRSFPILASSG 34 6.8 4.2
CBU 1157108–122 LSLMLNYPNSADRYY 1040 4.8 -
CBU 1157177–191 DLRYHAPIYGAVHPR 193 3.7 3.8
CBU 1645196–210 YDSLTTPTASVCQSE 620 4.1 3.5
CBU 1645272–286 RLVGSFPAEERIGRT 1858 3.5 -
CBU 191045–59 HYLVNHPEVLVEASQ 293 23.8 28.3
CBU 191083–97 KLFNDPASPVAGNPH 351 3.7 3.8
aMice were subcutaneously vaccinated with 10 ug PI-WCV/mouse(IFA+CpG) for 10 days. Peptide at 1 ug/ml. Three Independent experiment (n = 6). T cells were tested
in ELISPOT assays for IFN-g production. Data is presented as Stimulation index (SI), calculated as the number of spot forming cells after peptide stimulation divided by
spot forming cells in background. SI.2 was used as cut-off for positive response.
bMice were intratracheally infected using 106 C. burnetii RSA439 strain for 12 days. Peptide at 1 ug/ml. Three independent experiment (n = 4). ELISPOT assays were
performed as for post-vaccination.
doi:10.1371/journal.pone.0017712.t002
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infection (.20 SFC/106 cells, SI.2 with a p,0.05). All 9 peptides
were also recognized in PI-WCV vaccinated mice. By far
the strongest response in both cases was directed against CBU
191045–59. The next two highest responses were in both cases
directed against CBU 038369–83 and CBU 115763–77. Only two
peptides (CBU 1157108–122 and CBU 1645272–286) with low
responses following vaccination did not meet the significance
cutoff for recognition following infection (Table 2). Overall, these
results indicate that C. burnetii vaccination and infection lead to
essentially identical spectrum of epitopes recognized.
Characterization of the H-2 I-Ab restricted epitope by
ICCS
We used an ICCS assay to obtain the frequency of peptide
specific IFN-c producing CD4+ T cells after PI-WCV vaccination.
Figure 2 shows a representative experiment using the 8 optimal
peptides that elicited IFN-c production in both rAgs and PI-WCV
immunized mice in ELISPOT assays. The results from four
independent experiments are summarized in Table 2. The
frequency of responding cells ranged from 0.03% to 0.11%. All
peptides induced IFN-c responses .1 SD above background
cutoff (0.025%) and 5 of 8 peptides induced .2 SD above
background (0.034%).
Next, we wanted to assess the fraction of the total response
accounted for by the identified epitopes. As shown in Figure 2,
3.8% of the total CD4+ T cells from PI-WCV vaccinated mice
produced IFN-c upon stimulation with C. burnetii lysate (NM I
lysate). A pool of the 8 optimal epitopes induced a response of
0.3%. Based on these data, the peptides identified represent targets
of about 8% of the total specific IFN-c+CD4+ response induced by
PI-WCV vaccination.
Recent studies suggested that multifunctional, high-level
cytokine-producing (IL-2, IFN-c and TNF-a) Th1 cells are
correlated with protection against many intracellular pathogen
infections, including HIV, Leishmania major and Mycobacterium
tuberculosis [39,40]. In order to determine the quality of PI-WCV
vaccination induced peptide specific CD4+ T cells, we performed
an in depth analysis of peptides specific Th1 cells induced by PI-
WCV vaccination. We found that all 8 epitopes can induce
detectable IL-2+ CD4+ T cell recall responses in PI-WCV
immunized mice (Figure S1). However, only two peptides (CBU
115763–77 and CBU 191045–59) induced detectable TNF-a
+ CD4+
T cell recall responses in PI-WCV immunized mice (Figure S2).
Multicolor analysis confirmed this observation that only a small
fraction of CBU 115763–77 and CBU 191045–59 specific IFN-c
producing CD4+ T cells secret TNF-a in PI-WCV immunized
mice. Due to the lack of TNF-a expression, none of PI-WCV
vaccination induced peptides specific CD4+ T cells were capable
of secreting high-level IL-2, IFN-c and TNF-a simultaneously
(Figure S3). Notably, only about 1.5% of T cells responding to PI-
WCV lysate overall were multifunctional. This suggests that either
multi-functional T cells are not required for the protective effect of
PI-WCV vaccination, or that the low number of multifunctional T
cells we observed can nevertheless contribute to protection.
H-2 I-Ab binding capacity of identified epitopes
To determine the MHC binding affinity for each of the
identified epitopes, we conducted MHC-peptide binding assays.
H-2b class II MHC was purified and quantitative inhibition
binding assays were performed for each peptide using IAb as
described in Materials and Methods and [41]. The binding assays
revealed that all of the identified peptides bound to IAb with
significant affinities in the range of 34 – 1858 nM (Table 2). Six of
the eight peptides bound with affinities higher than 1,000 nM.
This is consistent with previous studies of class II binding which
found that the majority of epitopes have affinities above this
threshold [42]. Taken together, these data further characterize the
epitopes identified and support their putative I-Ab restriction,
assigned on the basis of the recognition by CD4+ T cells.
Immunization with peptide CBU 038369–83 did not
protect from challenge
Immunization with the whole cell vaccine induces protective
immunity from challenge with virulent C. burnetii organisms (45).
We tested if immunization with a CD4+ epitope would induce a
measurable protective effect. We chose peptide CBU 038369–83 for
these experiments as it induced one of the three strongest
responses, and we had sufficient amounts of purified material
available. Four groups of mice were immunized with either the
epitope, heat killed C. burnetii as a positive control, PBS (sham) or
an irrelevant CD4+ epitope (OVA), respectively. Body weights
were recorded at 2–4 day intervals after infection with C. burnetii
Nine Mile phase I through 14 days p.i. The mice were sacrificed
and lungs removed for PCR analysis and spleens weighed.
Examination of the body weights indicated that at days 7 and
10, mice immunized with the heat killed C. burnetii control lost
significantly less weight than mice immunized with either OVA or
the epitope (p,0.01) (Figure S4). However, no protective effect of
the epitope immunization was detectable by either weight loss,
spleen size on day 14, or bacterial burden in the lung detected by
PCR (data not shown). We conclude that immunization with this
peptide alone is insufficient to convey measurable protective
immunity against respiratory C. burnetii infection. Additional
experiments will be necessary to assess the protective capacity of
the other identified epitopes and of epitope pools.
Antigen specific linkage between CD4+ T cell help and
antibody production
Next, we wanted to explore what causes a significant fraction
of CD4+ responses to target antigens that are also targeted by
antibody responses. In particular, we wanted to test if T cells
predominantly provide help for antibody responses against the
source antigen of their target epitope. Such a functional
correlation between antibody and CD4+ response targets was
previously found in Vaccinia Virus [31]. In order to determine
linkage between antibody production and CD4+ T cell specificity
in PI-WCV vaccinated mice, C57BL/6 mice were immunized
with representative CD4+ epitopes from three different antigens
(CBU 038369–83, CBU 1157177–191 and CBU 191043–57) followed
by PI-WCV vaccination 10 days later. Sera were collected each
week after vaccination to measure IgG reactivity against the
three corresponding proteins. Peptide immunization alone did
not generate detectable antibodies against any tested recombi-
nant proteins (Figure 3A), which indicates that these three
peptides do not contain B cell epitopes that elicit antibody
production against their source antigen. The frequency of
epitope specific IFN-c producing CD4+ T cells was measured
at 28 days post PI-WCV vaccination (Figure 3B and 3C). All
mice receiving peptide immunizations contained more peptide-
specific CD4+ T helper cells compared to the mice in the sham
immunization group, which received PI-WCV immunization
without any peptide priming. This result demonstrates that
epitope specific CD4+ T cells were successfully primed by
peptide immunization.
The presence of CD4+ help for B cells producing antibodies
against each of the three antigens was determined by comparing
antibody titers with and without peptide immunization. Surpris-
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ingly, the pattern of help provided proved to be different for all
three antigens (Figure 3D): Immunization with any of the three
peptides provided nonspecific help for IgG antibody production
against CBU 1910 by 21 days post PI-WCV vaccination
compared to the sham control group. None of the three peptide
immunizations improved anti-CBU 1157 IgG antibody produc-
tion compared to the sham immunization control group. Finally,
only peptide CBU 038369–83 immunization provided specific help
for anti-CBU 0383 IgG antibody production beginning 7 days
post PI-WCV vaccination. These results suggest that undefined
antigen specific factors influence whether a linkage between
antibody and CD4+ T cell responses is established.
Discussion
Several studies suggest that T cells, especially CD4+ T cells, play
pivotal roles in vaccine derived protective immunity against C.
burnetii infection. However, little is known about how CD4+ T cells
are generated in response to C. burnetii PI-WCV vaccination and
what their molecular targets are. One reason for this gap in
Figure 3. Selective protein-specific CD4+ T cell help to B cells after peptide and PI-WCV vaccination. Four group of C57BL/6 mice (n = 5)
were primed with three C. burnetii CD4+ epitopes (CBU 038369–83,CBU 1157177–191 and CBU 191043–57) in the context of IFA and CpG or adjuvant
alone, followed by PI-WCV vaccination 10 days later. (A) IgG antibody responses to three individual C. burnetii proteins after twice peptide
vaccination. (B) At 28 days post PI-WCV vaccination, splenocytes from peptide and PI-WCV immunized mice were stimulated with peptides and lysed
Nine Mile Phase I C. burnetii respectively, for 20 hours. Samples were subsequently stained for intracellular IFNc and CD40L. Gated CD4+ lymphocytes
are shown, and quantified percentages represent CD4+IFNc+CD40L+ T cells. (C) Frequency of peptide specific IFN-c producing CD4+ T cells at 28 days
post PI-WCV vaccination. (D) IgG antibody responses to each C. burnetii protein at 0 days, 7days, 14 days, 21 days and 28 days post PI-WCV
vaccination. *P,0.05, **P,0.01, ***P,0.001
doi:10.1371/journal.pone.0017712.g003
Figure 2. CD4+ T cells recognition of PI-WCV derived H-2 I-Ab epitopes in IFN-c ICCS assays. CD4+ T cells recognition of positive peptides
identified by IFN-c ELISPOT were tested in ICCS assay. Ten ug of each peptide was used to stimulate 26106 lymphocytes from three mice immunized
with PI-WCV in the context of IFA and CpG 10 days earlier. Pool 8 used a mixture of eight peptides, which represents 8 different epitopes. A
representative experiment of four total experiments is shown in (A). Percentages of IFNc producing CD4+ T cells following stimulation with lysed Nine
Mile phase I C. burnetii and peptides are shown. A peptide was considered positive if the average of the individual experiments resulted in at least.1
SD above background (Medium +DMSO). Panel B shows the average frequency and standard deviation of epitope specific IFNc producing CD4+ T
cells from four-independent experiments.
doi:10.1371/journal.pone.0017712.g002
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knowledge is that traditional CD4+ T cell antigen screening and
epitope mapping methods are hampered by the large genome size
of bacteria including C. burnetii. Bioinformatics predictions of
peptide:MHC binding have been successfully utilized to identify
peptide candidates for epitope mapping [43]. However, the
number of candidate peptides predicted for CD4+ epitopes in C.
burnetii is in the order of several thousands. We examined whether
a strong B cell response against an antigen is accompanied by a
CD4+ T cell response, and if such a correlation could be utilized as
a mapping strategy of CD4+ responses in C. burnetii. More than 20
immunodominant proteins, which have significantly elevated IgG
antibody titer after infection or PI-WCV vaccination, have been
identified and characterized in several studies [32,33,34,35,36].
Presumably, these proteins are preferably targeted by B cells
because they are either abundant in C. burnetii or because B cells
targeting them receive preferential CD4+ T cell help, which is
required for B cell proliferation and Ig isotype switching. As
expected, a comparison of PI-WCV generated antibodies in B6
and MHCII knock-out mice showed that generating IgG
antibodies against these proteins required MHCII mediated
CD4+ T cell help (Figure 1). Therefore we screened for CD4+
epitopes in proteins that are known to be targeted by B cell
responses.
The applied B cell antigen-guided mapping strategy identified
CD4+ T cell epitopes in C. burnetii with a similar success rate as was
reported in viruses with about ,10 fold smaller genomes. Using
bioinformatic predictions, we identified a set of 117 predicted H-2
IAb binding peptides in 7 proteins targeted by B cell responses. We
screened these peptides for recognition in B6 mice vaccinated with
PI-WCV, and identified 8 distinct C. burnetii CD4+ T cell epitopes.
This hit rate (8/117 = 7%) compared favorably with a recent study
mapping class II epitopes in Vaccinia Virus [43] which screened
2146 peptides and identified 14 epitopes (0.7% hit rate). In
another recent study [44], 200 predicted high affinity binding
peptides from MCMV were screened and 15 epitopes identified
( = 7.5% hit rate). This demonstrates that at least a subset of CD4+
epitopes can be efficiently identified by predictions of MHC class
II binding peptides in proteins known to be targeted by B cell
responses. The identified epitopes provide the first insights into the
targets of CD4+ responses in C. burnetii. No responses were
detected against the CBU 0008, CBU 0311 and CBU 1869
proteins, which suggests that these proteins are weakly immuno-
genic for CD4+ T cells in mice. Approximately one-half of the
epitopes recognized following immunization with recombinant
antigens were also recognized following PI-WCV vaccination and
infection, which confirmed the immunogenic nature of these
antigens. Among the 8 identified epitopes, the frequency of CBU
191045–59 specific CD4
+ T cells (Table 2 and Figure 2) was much
higher than for other epitopes. Interestingly, CBU 1910 was also
the protein against which the highest antibody titers were detected
(Figure 1). Peptides from this antigen are now being examined for
their potential to serve as a correlate of protection for C. burnetii
vaccine efficacy in the murine system, and to assess the potential
for developing an IFN-c based immunodiagnostic assay, which
could provide direction for more accurate human Q fever
diagnosis.
We estimated the fraction of the total CD4+ response targets
accounted for by the 8 identified epitopes by comparing to the
response against whole C. burnetii extract. In FACS assays, 3.8% of
CD4+ cells produced IFN-c when stimulated by the extract. In
comparison, a pool of the 8 peptides stimulated 0.3% of the CD4+
cells, which corresponded to about 8% of the extract response.
While identification of only a small fraction of the total response
was an expected limitation of our screening strategy, we aimed at
identifying the most likely targets of responses rather than
achieving complete coverage. A second limitation to our screen
is that it only characterized IFN-c producing T cells. We predicted
that Th1 cells that secret IFN-c are critical to confer PI-WCV
derived protective immunity against C. burnetii infection. However,
additional CD4+ T cell epitopes may exist in our original pool that
do not induce IFN-c, but do trigger production of other cytokines,
such as IL-2, IL-4, IL-10 or TNF-a.
Earlier studies have reported deterministic linkages of antigen
specificities [31]. For example, immunization with CD4+ epitopes
provided specific help for B cells recognizing that antigen. While
the mechanism behind this effect was not determined, the authors
suggested that antigen uptake by B cells may not involve
internalization of whole viral particles, resulting in selective
antigen presentation by different B cells via MHC class II and
selective help by CD4+ T cells. We tested if a similar linkage
between antibody production and CD4+ T cell specificities was
present in the epitopes identified in our study. Surprisingly, we
found a diverse pattern of linkage for three epitopes from three
proteins. Mice immunized with each of three peptides enhanced
anti-CBU 1910 IgG antibody production after PI-WCV vaccina-
tion. Alternatively, only one peptide (CBU 038369–83) induced
CD4+ T cells that provided specific help for anti-CBU 0383 IgG
production in PI-WCV vaccinated mice. None of the peptides
induced help for anti-CBU 1157 IgG production. These data
suggest that the linkage between CD4+ help and antibody
responses in the PI-WCV vaccination model is complex and
epitope specific.
We speculate that the reason for this complex linkage is that B
cells utilize multiple mechanisms to sample C. burnetii antigens after
PI-WCV vaccination which do not always involve the internali-
zation of whole killed bacteria. Specifically, we propose two
models. The first model proposes that two formats of antigens,
soluble proteins and intact C burnetii bacteria, are recognized by B
cells through different routes, which is well documented by several
studies [45,46,47,48,49,50,51]. In this model, membrane associ-
ated proteins (like CBU 1910) are always recognized and
internalized by B cells together with other bacterial components,
and these antigen specific B cells in turn receive more nonspecific
CD4+ T cell help for proliferation and IgG antibody production.
In contrast, cytoplasmic proteins (like CBU 0383) that are
processed individually by cognate B cells after being released by
bacteria only receive help from CD4+ T cells specific for the same
antigen. This model also explains our observation that PI-WCV
vaccination can induce significantly more IgG antibody responses
to membrane-associated proteins than soluble extraction of
C.burnetii (data not shown). A second model proposes selective
antigen presentation at the postendocytic level by more specific
targeting mechanisms. Endocytosis of antigen is not necessarily
sufficient to ensure efficient antigen presentation [52]. Different C.
burnetii protein antigens may utilize different B cell surface receptor
for oligomerization, which could affect sorting along the endocytic
pathway. Different postendocytic sorting steps may affect T cell
epitopes that are processed by B cells [52,53]. Further studies are
required to discriminate between these two mechanisms.
In conclusion, our data demonstrate the feasibility of using
antibody responses and MHC class II binding predictions to
identify targets of CD4+ T cell responses in PI-WCV vaccinated
mice. Using some of these newly identified CD4+ epitopes, we
conclude that B cells processing Coxiella may involve multiple,
distinct mechanisms with an intricate linkage between antibody
production and CD4+ T cell specificities. The fact that not all
CD4+ epitopes provided help for IgG production against their
source antigens suggests that antigens against which no IgG
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production can be detected may well harbor targets of CD4+
responses. Finally, eight newly identified CD4+ T cell epitopes will
provide new reagents for tracking and analyzing the immune
responses targeting C. burnetii.
Materials and Methods
Bacteria
C. burnetii Nine Mile phase I (RSA 493) and Nine Mile phase II
(RSA 439) were grown in embryonated chicken eggs, purified by
gradient centrifugation, and inactivated by electronic beam
irradiation (32).
Cloning and expression of recombinant proteins
Open reading frames corresponding to C. burnetii immunoreac-
tive proteins were amplified by PCR and cloned into the pBAD/
TOPO ThioFusion expression vector (Invitrogen, Carlsbad, CA).
Recombinant proteins were expressed as 66His-tagged fusion
proteins in E. coli Top 10 and purified by nickel affinity
chromatography (Invitrogen).
CD4+ T cell epitope prediction and peptides synthesis
Seven protein antigens were selected for T cell epitopes
mapping; CBU 0311(P1), CBU 1910(Com1), CBU 1645(DotB),
CBU 0383(DNA-3-methyladenine glycosidase I), CBU 1157(lipo-
protein), CBU 0008(hypothetical protein) and CBU 1869(hypo-
thetical protein). The protein sequences were scanned for 15-mer
peptides predicted to bind with high affinity to H-2 I-Ab, using a
consensus approach described in [44]. Briefly, predictions were
obtained from the ARB and SMM-align tool on the IEDB website
[54], and all peptides were ranked according to their predicted
affinity by each method. The median of the three ranks was used
to select peptides for screening. A set of 117 different peptides were
synthesized as crude material (A&A Labs, San Diego, CA) and
used in initial screening experiments. Peptides used in immuni-
zation experiments were re-synthesized as purified material.
Mouse procedures and immunization
C57BL/6J (B6) mice were purchased from Jackson Laboratory
(Bar Harbor, ME) and bred in our facility. For screening CD4
epitopes, six-weeks old female B6 mice were subcutaneously (s.c.)
vaccinated with 20 mg of each protein antigen in the context of
complete Freud’s adjuvant. Nine days later, CD4+ T cells were
magnetically (MACS Miltenyibiotec, Auburn, CA) purified from
spleen and lymph node preparations. For epitope and antibody
linkage experiments, six-week old female B6 mice received single
immunization with selected peptides in the context of incomplete
Freud’s adjuvant (IFA) and CpG oligonucleotide. Ten days later,
primed mice were vaccinated with 2 mg PI-WCV in the context of
IFA. During each vaccination, the same adjuvant without any
antigen was used as sham control. Blood was collected at 7, 14, 21
and 28 days post PI-WCV vaccination. All procedures were
performed under animal protocols approved by the University
Laboratory Care Committee of Texas A&M University.
ELISA
Microplates (96 well, Fisher Scientific, Pittsburgh, PA) were
coated overnight at 4uC with 100 ml of 2 mg/ml antigen solution.
Plates were then blocked with 200 ml of 0.5% nonfat milk for 2 h
at 37uC. Individual mouse serum was diluted (1:50) and applied to
the assay wells. Specific IgG was detected using goat anti-mouse
IgG HRP conjugate (Bio-Rad, Hercules, CA) and OPD
peroxidase (Sigma, St. Louis, MO) by measuring OD in a Spectra
Max M2 plate reader (Molecular Devices, Sunnyvale, CA).
ELISPOT
Draining lymph nodes and spleen were pooled for each animal
9–12 days post vaccination. Then, CD4+ T cells were purified by
CD4 (L3T4) magnetic micro-beads (Miltenyibiotec) and antigen
specific IFN-c recall responses were measured by ELISPOT. For
individual mouse samples (n = 6), we incubated 26105 purified
CD4+ T cells in triplicate with 16105 naı¨ve lymphocytes and 1 mg
purified recombinant proteins (or peptide) in a total volume of
100 ml at 37uC. The frequency of IFN-c producing cells was
quantified 20 h later by ELISPOT Readers (Autoimmun
Diagnostika GmbH, Strassberg, Germany).
H-2 I-Ab peptide binding assays
Peptide binding assays were performed by using purified H-2b
class II MHC, essentially as previously described [41]. Briefly,
mouse B-cell lymphoma LB27.4 cells were utilized as sources of
murine IAb. MHC molecules were purified by affinity chroma-
tography using the anti-IAb monoclonal antibody Y3JP. Quanti-
tative peptide binding assays were based on the inhibition of
binding of radiolabeled probe peptide ROIV (peptide 569.01, an
artificial ligand with sequence YAHAAHAAHAAHAAHAA) to
purified IAb molecules. Assays were performed at pH 5.5 in PBS
containing 1% digitonin and in the presence of a cocktail of
protease inhibitors [41]. MHC binding of the radiolabeled peptide
was determined by capturing MHC-peptide complexes on
antibody-coated Lumitrac 600 plates (Greiner Bio-one, Frick-
enhausen, Germany) and measuring bound cpm using the
TopCount (Packard Instrument Co., Meriden, CT) microscintilla-
tion counter. The average 50% inhibitory concentration (IC50) of
ROIV (peptide 569.01) for IAb was 28 nM.
Flow cytometry and intracellular cyctokine staining
(ICCS) assay
46106 splenocytes (pooled from three mice that were immunized
for PI-WCV for 10 days) were either treated with 10 ug/ml
peptides or 3 ug/ml C. burnetii Nine Mile phase I strain lysate for
18 h. Then, GolgiPlug (BD Pharmingen) was added and cells were
cultured for another 6 h. Cells were incubated with the viability dye
ViViD (Molecular Probes), followed by intracellular staining for
PE-Cy7-anti-mouse CD3, APC-Cy7-antimouse CD4, FITC-anti-
mouse-IL-2, PerCP-Cy5.5-anti-mouse-TNF-a and APC-anti-
mouse IFN-c antibodies (Biolegend, San Diego, CA) according to
the manufacturer’s instructions. At least 16106 events per sample
were collected using a FACSAriaII (BD Biosciences) and data were
analyzed with FlowJo software (TreeStar, Ashland, OR). Back-
ground values were determined from cells pulsed with DMSO only.
Three independent experiments were performed for each peptide.
CD40L was stained in a same manner as described above by using
PE labeled anti-mouse CD154 antibody (Biolegend).
Challenge experiments
6 to 8 week old male C57BL/6J (B6) mice, bred in the
Montana State University facility were subcutaneously (s.c.)
inoculated with 20 mg of each epitope or 50 mg Ova (Voigt
Global Distribution, Laurence, KS) in the context of complete
Freud’s adjuvant, 100 ml PBS or 108 genome copies of heat killed
C. burnetii RSA 493 in 100 ml. 13 days post inoculation mice were
infected intratracheally with 103 genome copies of C. burnetii
RSA 493. 14 days post infection mice were euthanized by
phenobarbital anesthesia followed by exsanguination. Half of the
lungs were removed, homogenized in DMEM with 10% FBS,
then frozen for future DNA extraction and quantitative real time
PCR.
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Body weights were recorded at 2–3 day intervals after infection
with C. burnetii. Statistical analysis was conducted using a one-way,
non-parametric, ANOVA test followed by post-test Tukey analysis
for experiments with more than 2 groups and experiments with 2
groups were analyzed using an unpaired t test. Differences were
considered significant when p,0.05. For quantitative PCR, DNA
was extracted from lung and spleen homogenates using a Qiagen
DNeasy blood and tissue kit according to manufacturer’s instruc-
tions. DNA was used as a template for quantitative real time PCR
with SYBRH Green PCR Master Mix (Applied Biosystems, Foster
City, CA) by quantifying C. burnetii genome copies from amplified
rpoS gene copies. Determination of the number of genome copies
per organ were carried out as described previously [55].
Supporting Information
Table S1 Complete peptide set and screening results.
(DOC)
Figure S1 CD4+ T cells recognition of PI-WCV derived
H-2 I-Ab epitopes in IL-2 ICCS assays. CD4+ T cells
recognition of positive peptides identified by IFN-c ELISPOT
were tested in ICCS assay. 10 ug of each peptide was used to
stimulate 26106 lymphocytes from four mice immunized with PI-
WCV 10 days earlier in the context of IFA and CpG. A
representative experiment of four total experiments is shown.
Percentages of IL-2 producing CD4+ T cells following stimulation
with lysed Nine Mile phase I C. burnetii and peptides are shown. A
peptide was considered positive if the average of the individual
experiments resulted in at least .1 SD above background
(0.009%, Medium +DMSO).
(TIF)
Figure S2 CD4+ T cells recognition of PI-WCV derived
H-2 I-Ab epitopes in TNF-a ICCS assays. CD4+ T cells
recognition of positive peptides identified by IFN-c ELISPOT
were tested in ICCS assay. 10 ug of each peptide was used to
stimulate 26106 lymphocytes from four mice immunized with PI-
WCV 10 days earlier in the context of IFA and CpG. A
representative experiment of four total experiments is shown.
Percentages of TNF-a producing CD4+ T cells following
stimulation with lysed Nine Mile Phase I C. burnetii and peptides
are shown. A peptide was considered positive if the average of the
individual experiments resulted in at least .1 SD above
background (0.011%, Medium +DMSO).
(TIF)
Figure S3 Multiparameter analysis of PI-WCV vaccina-
tion induced peptides specific CD4+ T cells. CD4+ T cells
recognition of positive peptides identified by IFN-c ELISPOT
were tested in multicolor ICCS assay as described in material and
methods. 10 ug of each peptide was used to stimulate 26106
lymphocytes from four mice immunized with PI-WCV 10 days
earlier in the context of IFA and CpG. Cells were gated on viable
CD3+CD4+IFN-c+ T cells. A representative experiment of four
total experiments is shown. Percentages of TNF-a producing
CD4+ T cells following stimulation with lysed Nine Mile phase I C.
burnetii and peptides are shown.
(TIF)
Figure S4 Peptide immunization does not protect from
weight loss after challenge or bacterial burden. A)
Change in body weights of C57BL/6 mice immunized with either
PBS alone, OVA or epitope CBU 038369–83 in the context of
CFA, or PI-WCV. After intratracheal infection with 103 genome
copies of C. burnetii Nine Mile phase I, body weight change was
expressed as a percentage of the initial body weight prior to
infection and significant differences were identified at days 7 and
10 p.i. (p,0.01). No protective effect of the epitope immunization
was observed in comparison to the immunization with PBS or the
irrelevant OVA epitope. Data is representative of one of two
independent experiments with 4–5 mice per group. B) 14 days post
infection mice were euthanized and the bacterial burden in the
lung was determined by PCR. No protective effect of the epitope
immunization was observed in comparison to the immunization
with PBS or the irrelevant OVA epitope. In contrast, immuniza-
tion with heat killed PI-WCV (positive control) resulted in
significantly lower bacterial burden (p,0.01).
(TIF)
Acknowledgments
We want to thank Nancy Walters, Sarah Golden and Sara Erickson for
technical help with the challenge experiments.
Author Contributions
Conceived and designed the experiments: CC JES BP. Performed the
experiments: CC CD PW JES AR. Analyzed the data: CC CD AR AGH
JES BP. Contributed reagents/materials/analysis tools: PW JES. Wrote the
paper: CC BP.
References
1. Maurin M, Raoult D (1999) Q fever. Clin Microbiol Rev 12: 518–553.
2. Parker NR, Barralet JH, Bell AM (2006) Q fever. Lancet 367: 679–688.
3. Ackland JR, Worswick DA, Marmion BP (1994) Vaccine prophylaxis of Q fever.
A follow-up study of the efficacy of Q-Vax (CSL) 1985-1990. Med J Aust 160:
704–708.
4. Marmion BP, Ormsbee RA, Kyrkou M, Wright J, Worswick DA, et al. (1984)
Vaccine prophylaxis of abattoir-associated Q fever. Lancet ii: 1411–1414.
5. Ormsbee RA, Bell EJ, Lackman DB, Tallent G (1964) The influence of phase on
the protective potency of Q fever vaccine. J Immunol 92: 404–412.
6. Zhang G, Russell-Lodrigue KE, Andoh M, Zhang Y, Hendrix LR, et al. (2007)
Mechanisms of vaccine-induced protective immunity against Coxiella burnetii
infection in BALB/c mice. J Immunol 179: 8372–8380.
7. Kazar J, El-Najdawi E, Brezina R, Schramek S (1977) Search for correlates of
resistance to virulent challenge in mice immunized with Coxiella burnetii. Acta
Virol 21: 422–430.
8. Kazar J, Votruba D, Propper P, Schramek S (1986) Onset and duration of
immunity in guinea pigs and mice induced with different Q fever vaccines. Acta
Virol 30: 499–506.
9. Novak M, Brezina R, Kazar J (1992) Immunoblot analysis of antibody response
in mice infected with Coxiella burnetii phase I. Acta Virol 36: 39–44.
10. Vigil A, Ortega R, Nakajima-Sasaki R, Pablo J, Molina DM, et al. (2010)
Genome-wide profiling of humoral immune response to Coxiella burnetii infection
by protein microarray. Proteomics 10: 2259–2269.
11. Andoh M, Zhang G, Russell-Lodrigue KE, Shive HR, Weeks BR, et al. (2007) T
cells are essential for bacterial clearance, and gamma interferon, tumor necrosis
factor alpha, and B cells are crucial for disease development in Coxiella burnetii
infection in mice. Infect Immun 75: 3245–3255.
12. McHeyzer-Williams LJ, McHeyzer-Williams MG (2005) Antigen specific
memory B cell development. Annu Rev Immunol 23: 487–513.
13. Richards KA, Chaves FA, Krafcik FR, Topham DJ, Lazarski CA, et al.
(2007) Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an
exceptionally broad pattern of immunodominance in the primary HLA-DR1-
restricted CD4 T-cell response to influenza virus hemagglutinin. J Virol 81:
7608–7619.
14. Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, et al. (2005)
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated
activation-induced cell death. Nature 434: 88–93.
15. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, et al. (2003)
CD4+ T cells are required for secondary expansion and memory in CD8+ T
lymphocytes. Nature 421: 852–856.
Identification of C. burnetii CD4+ T Cell Epitopes
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e17712
16. Radosevic K, Wieland CW, Rodriguez A, Weverling GJ, Mintardjo R, et al.
(2007) Protective immune responses to a recombinant adenovirus type 35
tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope
mapping and role of gamma interferon. Infect Immun 75: 4105–4115.
17. Sporri R, Joller N, Albers U, Hilbi H, Oxenius A (2006) MyD88-Dependent
IFN-gamma production by NK cells is key for control of Legionella pneumophila
infection. J Immunol 176: 6162–6171.
18. Roshick C, Wood H, Caldwell HD, McClarty G (2006) Comparison of gamma
interferon-mediated antichlamydial defense Mmechanisms in human and mouse
cells. Infect Immun 74: 225–238.
19. Murphey C, Murthy AK, Meier PA, Neal Guentzel M, Zhong G, et al. (2006)
The protective efficacy of chlamydial protease-like activity factor vaccination is
dependent upon CD4+ T cells. Cellular Immunology 242: 110–117.
20. Brennan RE, Russell K, Zhang G, Samuel JE (2004) Both inducible nitric oxide
synthase and NADPH oxidase contribute to the control of virulent phase I
Coxiella burnetii infections. Infect Immun 72: 6666–6675.
21. Howe D, Barrows LF, Lindstrom NM, Heinzen RA (2002) Nitric oxide inhibits
Coxiella burnetii replication and parasitophorous vacuole maturation. Infect
Immun 70: 5140–5147.
22. Dellacasagrande J, Ghigo E, Raoult D, Capo C, Mege JL (2002) IFN-gamma-
induced apoptosis and microbicidal activity in monocytes harboring the
intracellular bacterium Coxiella burnetii require membrane TNF and homotypic
cell adherence. J Immunol 169: 6309–6315.
23. Morisawa Y, Wakiguchi H, Takechi T, Kurashige T, Nagaoka H (2001)
Intractable Q fever treated with recombinant gamma interferon. Pediatr Infect
Dis J 20: 546–547.
24. Brett SJ, Lamb JR, Cox JH, Rothbard JB, Mehlert A, et al. (1989) Differential
pattern of T cell recognition of the 65-kDa mycobacterial antigen following
immunization with the whole protein or peptides. Eur J Immunol 19:
1303–1310.
25. Bergman MA, Cummings LA, Alaniz RC, Mayeda L, Fellnerova I, et al. (2005)
CD4+-T-cell responses generated during murine Salmonella enterica serovar
Typhimurium infection are directed towards multiple epitopes within the natural
antigen FliC. Infect Immun 73: 7226–7235.
26. Cookson BT, Bevan MJ (1997) Identification of a natural T cell epitope
presented by Salmonella-infected macrophages and recognized by T cells from
orally immunized mice. J Immunol 158: 4310–4319.
27. Scherle PA, Gerhard W (1986) Functional analysis of influenza-specific helper T
cell clones in vivo. T cells specific for internal viral proteins provide cognate help
for B cell responses to hemagglutinin. J Exp Med 164: 1114–1128.
28. Russell SM, Liew FY (1979) T cells primed by influenza virion internal
components can cooperate in the antibody response to haemagglutinin. Nature
280: 147–148.
29. Bynoe MS, Viret C, Flavell RA, Janeway CA, Jr. (2005) T cells from
epicutaneously immunized mice are prone to T cell receptor revision. Proc Natl
Acad Sci U S A 102: 2898–2903.
30. Lake P, Mitchison NA (1976) Associative control of the immune response to cell
surface antigens. Immunol Commun 5: 795–805.
31. Sette A, Moutaftsi M, Moyron-Quiroz J, McCausland MM, Davies DH, et al.
(2008) Selective CD4+ T cell help for antibody responses to a large viral
pathogen: deterministic linkage of specificities. Immunity 28: 847–858.
32. Hendrix LR, Samuel JE, Mallavia LP (1990) Identification and cloning of a 27-
kDa Coxiella burnetii immunoreactive protein. Ann N Y Acad Sci 590: 534–540.
33. Zhang G, Kiss K, Seshadri R, Hendrix LR, Samuel JE (2004) Identification and
cloning of immunodominant antigens of Coxiella burnetii. Infect Immun 72:
844–852.
34. Zhang G, To H, Russell KE, Hendrix LR, Yamaguchi T, et al. (2005)
Identification and characterization of an immunodominant 28-kilodalton Coxiella
burnetii outer membrane protein specific to isolates associated with acute disease.
Infect Immun 73: 1561–1567.
35. Zhang GQ, Samuel JE (2003) Identification and cloning potentially protective
antigens of Coxiella burnetii using sera from mice experimentally infected with
Nine Mile phase I. Ann N Y Acad Sci 990: 510–520.
36. Beare PA, Chen C, Bouman T, Pablo J, Unal B, et al. (2008) Candidate antigens
for Q fever serodiagnosis revealed by immunoscreening of a Coxiella burnetii
protein microarray. Clin Vaccine Immunol 15: 1771–1779.
37. Varghees S, Kiss K, Frans G, Braha O, Samuel JE (2002) Cloning and porin
activity of the major outer membrane protein P1 from Coxiella burnetii. Infect
Immun 70: 6741–6750.
38. Wang P, Sidney J, Dow C, Mothe B, Sette A, et al. (2008) A systematic
assessment of MHC class II peptide binding predictions and evaluation of a
consensus approach. PLoS Comput Biol 4: e1000048.
39. Darrah PA, Patel DT, De Luca PM, Lindsay RWB, Davey DF, et al. (2007)
Multifunctional TH1 cells define a correlate of vaccine-mediated protection
against Leishmania major. Nat Med advanced online publication.
40. Forbes EK, Sander C, Ronan EO, McShane H, Hill AVS, et al. (2008)
Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not
spleen, correlate with protection against Mycobacterium tuberculosis aerosol
challenge in mice. pp 4955–4964.
41. Sidney J, Southwood S, Oseroff C, del Guercio MF, Sette A, et al. (2001)
Measurement of MHC/peptide interactions by gel filtration. Curr Protoc
Immunol Chapter 18: Unit 18 13.
42. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, et al. (1998)
Several common HLA-DR types share largely overlapping peptide binding
repertoires. J Immunol 160: 3363–3373.
43. Moutaftsi M, Bui HH, Peters B, Sidney J, Salek-Ardakani S, et al. (2007)
Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely
distinct from those targeted by CD8+ T cell responses. J Immunol 178:
6814–6820.
44. Arens R, Wang P, Sidney J, Loewendorf A, Sette A, et al. (2008) Cutting edge:
murine cytomegalovirus induces a polyfunctional CD4 T cell response.
J Immunol 180: 6472–6476.
45. Farr AG, Cho Y, De Bruyn PP (1980) The structure of the sinus wall of the
lymph node relative to its endocytic properties and transmural cell passage.
Am J Anat 157: 265–284.
46. Szakal AK, Holmes KL, Tew JG (1983) Transport of immune complexes from
the subcapsular sinus to lymph node follicles on the surface of nonphagocytic
cells, including cells with dendritic morphology. J Immunol 131: 1714–1727.
47. Wykes M, Pombo A, Jenkins C, MacPherson GG (1998) Dendritic cells interact
directly with naive B lymphocytes to transfer antigen and initiate class switching
in a primary T-dependent response. J Immunol 161: 1313–1319.
48. Colino J, Shen Y, Snapper CM (2002) Dendritic cells pulsed with intact
Streptococcus pneumoniae elicit both protein- and polysaccharide-specific immuno-
globulin isotype responses in vivo through distinct mechanisms. J Exp Med 195:
1–13.
49. Qi H, Egen JG, Huang AY, Germain RN (2006) Extrafollicular activation of
lymph node B cells by antigen-bearing dendritic cells. Science 312: 1672–1676.
50. Batista FD, Harwood NE (2009) The who, how and where of antigen
presentation to B cells. Nat Rev Immunol 9: 15–27.
51. Phan TG, Grigorova I, Okada T, Cyster JG (2007) Subcapsular encounter and
complement-dependent transport of immune complexes by lymph node B cells.
Nat Immunol 8: 992–1000.
52. Watts C (1997) Capture and processing of exogenous antigens for presentation
on MHC molecules. Annu Rev Immunol 15: 821–850.
53. Mitchell RN, Barnes KA, Grupp SA, Sanchez M, Misulovin Z, et al. (1995)
Intracellular targeting of antigens internalized by membrane immunoglobulin in
B lymphocytes. J Exp Med 181: 1705–1714.
54. Chen C, Bouman TJ, Beare PA, Mertens K, Zhang GQ, et al. (2009) A
systematic approach to evaluate humoral and cellular immune responses to
Coxiella burnetii immunoreactive antigens. Clin Microbiol Infect.
55. Coleman SA, Fischer ER, Howe D, Mead DJ, Heinzen RA (2004) Temporal
analysis of Coxiella burnetii morphological differentiation. J Bacteriol 186:
7344–7352.
56. Yu NY, Wagner JR, Laird MR, Melli G, Rey S, et al. (2010) PSORTb 3.0:
improved protein subcellular localization prediction with refined localization
subcategories and predictive capabilities for all prokaryotes. Bioinformatics 26:
1608–1615.
Identification of C. burnetii CD4+ T Cell Epitopes
PLoS ONE | www.plosone.org 10 March 2011 | Volume 6 | Issue 3 | e17712
